David Miller, MD

Professor
Endowed Title: Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Dallas Foundation Chair in Gynecologic Oncology
Obstetrics & Gynecology

Contact Information

UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390

Office Phone: 214-648-3639

david.miller@utsouthwestern.edu

To make an appointment, call 214-645-8300.

Biography

Dr. Miller is Director of Gynecologic Oncology, Professor of Obstetrics & Gynecology, and holds the Dallas Foundation Chair in Gynecologic Oncology. He serves as Medical Director of Gynecologic Oncology and Chair of the Cancer Committee for the Parkland Health and Hospital System. Long active in the development of clinical trials for the treatment of gynecologic cancers, he is Study Chair for multiple national trials of the Gynecologic Oncology Group, served on the Board of Directors, and is Chair of its Uterine Corpus Committee. The National Cancer Institute?s Cancer Therapy Evaluation Program recently appointed him to the Gynecologic Cancer Steering Committee. Dr. Miller attended the University of Oklahoma and graduated from its medical school. He completed residency in obstetrics and gynecology at the Hospital of the Medical College of Pennsylvania and then served as a fellow in reproductive endocrinology at the University of California, San Diego. He completed a fellowship in gynecologic oncology at Stanford University Medical Center. Prior to coming to Southwestern, he was Assistant Professor at the Medical University of South Carolina and then Northwestern University Medical School in Chicago.

Education

FellowshipStanford University Hospital (1985)
FellowshipUniversity of CA San Diego Med Ctr (1982)
ResidencyMedical College Hosp. of Pensylvania (1981)
InternshipMedical College of Pennsylvania (1978)
Medical SchoolUniversity of Oklahoma -Tulsa (1977)

Research Interests

Antineoplastic drug development
Clinical trials
Gynecologic Oncology
Reconstructive pelvic surgery

Publications

Featured
Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix

Bull-Phelps, S.L., Garner, E.I.O., Walsh, C.S., Gehrig, P.A., Miller, D.S., Schorge, J.O. , Gynecologic Oncology , November 2007; (107 (2)):316-319

Featured
Implications of EGFR inhibition in ovarian cancer cell proliferation

Bull Phelps, S.L., Schorge, J.O., Peyton, M.J., Shigematsu, H., Xiang, L.-L., Miller, D.S., Lea, J.S. , Gynecologic Oncology , June 2008; (109(3)):411-7

Featured
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

Miller, D.S., Blessing, J.A., Bodurka, D.C., Bonebrake, A.J., Schorge, J.O. , Gynecologic Oncology , July 2008; (110(1)):65-70

Featured
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

Long HJ 3rd. Bundy BN. Grendys EC Jr. Benda JA. McMeekin DS. Sorosky J. Miller DS. Eaton LA. Fiorica JV. , Journal of Clinical Oncology , July 2005; (23(21)):4626-33

Featured
Simplifying the preevacuation testing strategy for patients with molar pregnancy

Knowles, L.M., Drake, R.D., Ashfaq, R., Castrillon, D.H., Miller, D.S., Schorge, J.O. , The Journal of reproductive medicine , August 2007; (52 (8)):685-688

Featured
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

Moore DH. Blessing JA. McQuellon RP. Thaler HT. Cella D. Benda J. Miller DS. Olt G. King S. Boggess JF. Rocereto TF. , Journal of Clinical Oncology , August 2004; (22(15)):3113-9

Featured
The role of lymphadenectomy in endometrial cancer.

Kehoe SM, Miller DS, Clinical obstetrics and gynecology, 2011 Jun; 54 (2):235-44

Featured
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.

Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS, Gynecologic oncology, 2011 Apr; 121 (1):118-21

Featured
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.

Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010 Oct; 20 (7):1137-41

Featured
Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?

Boren TP, Miller DS, Women's health (London, England), 2010 Nov; 6 (6):789-95

Honors/Awards

Texas Super Doctors

Texas Monthly (2011)

The Best Doctors in Dallas

D Magazine (2011)

National Faculty Award

Council on Resident Education in Obstetrics & Gynecology (2000)

Senior Residents Award for Outstanding Faculty Teacher

Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas (2000)

First Prize Scientific Paper Award

American College of Obstetricians & Gynecologists, 39th Annual Meeting (1991)

Professional Associations/Affiliations

American College of Obstetricians & Gynecologists

American College of Surgeons

American Society of Clinical Oncology

Gynecologic Oncology Group

Society of Gynecologic Oncology